Access
To read this story in full you will need to login or make a payment (see right).
Letter
Nature Medicine 14, 1351 - 1356 (2008)
Published online: 30 November 2008 | doi:10.1038/nm.1890
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A Engelman1,2,3,12, Liang Chen4,5,12, Xiaohong Tan4,5, Katherine Crosby6, Alexander R Guimaraes7,8, Rabi Upadhyay7,8, Michel Maira9, Kate McNamara4,5, Samanthi A Perera4,5, Youngchul Song1, Lucian R Chirieac10, Ramneet Kaur1,3, Angela Lightbown6, Jessica Simendinger6, Timothy Li2, Robert F Padera10, Carlos García-Echeverría9, Ralph Weissleder7,8,11, Umar Mahmood7,8, Lewis C Cantley2,3,11 & Kwok-Kin Wong3,4,5
Abstract
Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-
catalytic subunit (encoded by PIK3CA)1. They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R). Although the p110- mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models. Furthermore, clinical trials with PI3K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies. In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p110- H1047R. Treatment of these tumors with NVP-BEZ235, a dual pan–PI3K and mammalian target of rapamycin (mTOR) inhibitor in clinical development, led to marked tumor regression as shown by positron emission tomography–computed tomography, magnetic resonance imaging and microscopic examination. In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to single-agent NVP-BEZ235. However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these Kras-mutant cancers. These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and, when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Genetic basis of salt-susceptibility in the Sabra rat model of hypertensionKidney International Original Article
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenograftsBritish Journal of Cancer Original Article
